Pathways Implicated in Tadalafil Amelioration of Duchenne Muscular Dystrophy

Journal of Cellular Physiology

Volumn 231, Issue 1, 2016, Pages 224-232

  De Arcangelis, Valeria ^a   Strimpakos, Georgios ^b   Gabanella, Francesca ^b   Corbi, Nicoletta ^c   Luvisetto, Siro ^b   Magrelli, Armando ^d   Onori, Annalisa ^c   Passananti, Claudio ^c   Pisani, Cinzia ^c   Rome, Sophie ^e   Severini, Cinzia ^b,f   Naro, Fabio ^a   Mattei, Elisabetta ^b   Di Certo, Maria Grazia ^b   Monaco, Lucia ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b CNR   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^e UNIVERSITÉ DE LYON   (France)

^f EUROPEAN BRAIN RESEARCH INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC GMP; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; TADALAFIL; PHOSPHODIESTERASE V INHIBITOR; PPARGC1A PROTEIN, MOUSE; TRANSCRIPTION FACTOR;

ANIMAL EXPERIMENT; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG EFFICACY; DUCHENNE MUSCULAR DYSTROPHY; FEMALE; FROZEN SECTION; GENE EXPRESSION; IN VITRO STUDY; LIPID METABOLISM; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; TREADMILL EXERCISE; UPREGULATION; ANIMAL; C57BL MOUSE; DRUG EFFECTS; GENETICS; METABOLISM; MUSCULAR DYSTROPHY, DUCHENNE; SKELETAL MUSCLE; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

ANIMALS; FEMALE; LIPID METABOLISM; MALE; MICE, INBRED C57BL; MICE, INBRED MDX; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; PHOSPHODIESTERASE 5 INHIBITORS; TADALAFIL; TRANSCRIPTION FACTORS; UP-REGULATION;

EID: 84942342503     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.25075     Document Type: Article

References (50)

1. Ahmadian M, Suh JM, Hah N, Liddle C, Atkins AR, Downes M, Evans RM. 2013. PPARγ signaling and metabolism: The good, the bad and the future. Nat Medicine 19:557-566.
2. Asai A, Sahani N, Kaneki M, Ouchi Y, Martyn JAJ, Yasuhara SE. 2007. Primary Role of Functional Ischemia, Quantitative Evidence for the Two-Hit Mechanism, and Phosphodiesterase-5 Inhibitor Therapy in Mouse Muscular Dystrophy. PLoS ONE 2:e806.
3. Balasubramanian S, Mani SK, Kasiganesan H, Baicu CC, Kuppuswamy D. 2010. Hypertrophic stimulation increases β-actin dynamics in adult feline cardiomyocytes. PLoS ONE 5:e11470.
4. Baltgalvis KA, Call JA, Nikas JB, Lowe DA. 2009. Effects of prednisolone on skeletal muscle contractility in mdx mice. Muscle Nerve 40:443-454.
5. Berardi E, Annibali D, Cassano M, Crippa S, Sampaolesi M. 2014. Molecular and cell-based therapies for muscle degenerations: A road under construction. Front Physiol 5:119.
6. Bishu K, Hamdani N, Mohammed SF, Kruger M, Ohtani T, Ogut O, Brozovich FV, Burnett JC, Jr., Linke WA, Redfield MM. 2011. Sildenafil and B-type natriuretic peptide acutely phosphorylate titin and improve diastolic distensibility in vivo. Circulation 124:2882-2891.
7. Boppart MD, De Lisio M, Zou K, Huntsman HD. 2013. Defining a role for non-satellite stem cells in the regulation of muscle repair following exercise. Front Physiol 4:310.
8. Bunnell TM, Burbach BJ, Shimizu Y, Ervasti JM. 2011. Actin specifically controls cell growth, migration, and the G-actin pool. Mol Biol Cell 22:4047-4058.
9. Colussi C, Mozzetta C, Gurtner A, Illi B, Rosati J, Straino S, Ragone G, Pescatori M, Zaccagnini G, Antonini A, Minetti G, Martelli F, Piaggio G, Gallinari P, Steinkuhler C, Clementi E, Dell'Aversana C, Altucci L, Mai A, Capogrossi MC, Puri PL, Gaetano C. 2008. HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment. Proc Natl Acad Sci USA 105:19183-19187.
10. Conti M, Beavo J. 2007. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: Essential components in cyclic nucleotide signaling. Ann Rev Biochem 76:481-511.
11. Coque E, Raoul C, Bowerman M. 2014. ROCK inhibition as a therapy for spinal muscular atrophy: Understanding the repercussions on multiple cellular targets. Front Neurosci 8:271.
12. Crescioli C, Sturli N, Sottili M, Bonini P, Lenzi A, Di Luigi L. 2013. Insulin-like effect of the phosphodiesterase type 5 inhibitor tadalafil onto male human skeletal muscle cells. J Endocrinol Invest 36:1020-1026.
13. D'Arcy CE, Feeney SJ, McLean CA, Gehrig SM, Lynch GS, Smith JE, Cowling BS, Mitchell CA, McGrath MJ. 2014. Identification of FHL1 as a therapeutic target for Duchenne muscular dystrophy. Hum Mol Genet 23:618-636.
14. D'Angelo MG, Gandossini S, Martinelli Boneschi F, Sciorati C, Bonato S, Brighina E, Comi GP, Turconi AC, Magri F, Stefanoni G, Brunelli S, Bresolin N, Cattaneo D, Clementi E. 2012. Nitric oxide donor and non steroidal anti inflammatory drugs as a therapy for muscular dystrophies: Evidence from a safety study with pilot efficacy measures in adult dystrophic patients. Pharmacol Res 65:472-479.
15. Di Certo MG, Corbi N, Strimpakos G, Onori A, Luvisetto S, Severini C, Guglielmotti A, Batassa EM, Pisani C, Floridi A, Benassi B, Fanciulli M, Magrelli A, Mattei E, Passananti C. 2010. The artificial gene Jazz, a transcriptional regulator of utrophin, corrects the dystrophic pathology in mdx mice. Hum Mol Genet 19:752-760.
16. Fairclough RJ, Wood MJ, Davies KE. 2013. Therapy for Duchenne muscular dystrophy: Renewed optimism from genetic approaches. Nat Rev Genet 14:373-378.
17. Forst J, Forst R, Leithe, Maurin N. 1998. Platelet function deficiency in Duchenne muscular dystrophy. Neuromuscular Disorders 8:46-49.
18. Friedrich O, Both M, Weber C, Schürmann S, Teichmann MD, von Wegner F, Fink RH, Vogel M, Chamberlain JS, Garbe C. 2010. Microarchitecture is severely compromised but motor protein function is preserved in dystrophic mdx skeletal muscle. Biophys J 98:606-616.
19. Gordon BS, Delgado Díaz DC, Kostek MC. 2013. Resveratrol decreases inflammation and increases utrophin gene expression in the mdx mouse model of Duchenne muscular dystrophy. Clin Nutr 32:104-111.
20. Grange RW 2013. Use of treadmill and wheel exercise to assess dystrophic state. Experimental Protocols for DMD Animal Models, chapter 9 (http://www.treat-nmd.eu/research/preclinical/dmd-sops/).
21. Handschin C, Kobayashi YM, Chin S, Seale P, Campbell KP, Spiegelman BM. 2007. PGC-1α regulates the neuromuscular junction program and ameliorates Duchenne muscular dystrophy. Genes Dev 21:770-783.
22. Hollinger K, Gardan-Salmon D, Santana C, Rice D, Snella E, Selsby JT. 2013. Rescue of dystrophic skeletal muscle by PGC-1α involves restored expression of dystrophin-associated protein complex components and satellite cell signaling. Am J Physiol Regul Integr Comp Physiol 305:R13-R23.
23. Huang DW, Sherman BT, Lempicki RA. 2009. Systematic and integrative analysis of large gene lists using DAVID Bioinformatics Resources. Nat Protocol 4:44-57.
24. Huang DW, Sherman BT, Lempicki RA. 2009a. Bioinformatics enrichment tools: Paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 37:1-13.
25. Jarmin S, Kymalainen H, Popplewell L, Dickson G. 2014. New developments in the use of gene therapy to treat Duchenne muscular dystrophy. Expert Opin Biol Ther 14:209-230.
26. Kawahara G, Gasperini MJ, Myers JA, Widrick JJ, Eran A, Serafini PR, Alexander MS, Pletcher MT, Morris CA, Kunkel LM. 2014. Dystrophic muscle improvement in zebrafish via increased heme oxygenase signaling. Hum Mol Genet 23:1869-1878.
27. Kobaiashi YM, Rader EP, Crawford RW, Iyengar NK, Thedens DR, Faulkner JA, Parikh SV, Weiss RM, Chamberlain JS, Moore SA, Campbell KP. 2008. Sarcolemma-localized nNOS is required to maintain activity after mild exercise. Nature 456:511-515.
28. Konieczny P, Swiderski K, Chamberlain JS. 2013. Gene and cell-mediated therapies for muscular dystrophy. Muscle Nerve 47:649-663.
29. Kornegay JN, Spurney CF, Nghiem PP, Brinkmeyer-Langford CL, Hoffman EP, Nagaraju K. 2014. Pharmacologic management of duchenne muscular dystrophy: Target identification and preclinical trials. ILAR J 55:119-149.
30. Ljubicic V, Khogali S, Renaud JM, Jasmin BJ. 2012. Chronic AMPK stimulation attenuates adaptive signaling in dystrophic skeletal muscle. Am J Physiol Cell Physiol 302:C110-C121.
31. Ljubicic V, Burt M, Lunde JA, Jasmin BJ. 2014. Resveratrol induces expression of the slow, oxidative phenotype in mdx mouse muscle together with enhanced activity of the SIRT1-PGC-1α axis. Am J Physiol Cell Physiol 307:C66-C82.
32. Martin EA, Barresi R, Byrne BJ, Tsimerinov EI, Scott BL, Walker AE, Gurudevan SV, Anene F, Elashoff RM, Thomas GD, Victor RG. 2012. Tadalafil Alleviates Muscle Ischemia in Patients with Becker Muscular Dystrophy. Sci Transl Med 4:162ra 155.
33. McFarlan JT, Yoshida Y, Jain SS, Han XX, Snook LA, Lally J, Smith BK, Glatz JF, Luiken JJ, Sayer RA, Tupling AR, Chabowski A, Holloway GP, Bonen A. 2012. In vivo, fatty acid translocase (CD36) critically regulates skeletal muscle fuel selection, exercise performance, and training-induced adaptation of fatty acid oxidation. J Biol Chem 287:23502-23513.
34. Mokni W, Keravis T, Etienne-Selloum N, Walter A, Kane MO, Schini-Kerth VB, Lugnier C. 2010. Concerted regulation of cCGMP and cCAMP phosphodiesterases in early cardiac hypertrophy induced by angiotensin II. PLoS ONE 5:e14227.
35. Movsesian MA, Kukreja RC. 2011. Phosphodiesterase inhibition in heart failure. Handb Exp Pharmacol 204:237-249.
36. Mozzetta C, Consalvi S, Saccone V, Tierney M, Diamantini A, Mitchell KJ, Marazzi G, Borsellino G, Battistini L, Sassoon D, Sacco A, Puri PL. 2013. Fibroadipogenic progenitors mediate the ability of HDAC inhibitors to promote regeneration in dystrophic muscles of young, but not old Mdx mice. EMBO Mol Med 5:626-639.
37. Nagayama T, Zhang M, Hsu S, Takimoto E, Kass DA. 2008. Sustained Soluble Guanylate Cyclase Stimulation Offsets Nitric-Oxide Synthase Inhibition to Restore Acute Cardiac Modulation by Sildenafil. J Pharmachol Exp Ther 326:380-387.
38. Percival JM, Adamo CA, Beavo JA, Froehner SC. 2011. Evaluation of the therapeutic utility of phosphodiesterase 5A inhibition in the mdx mouse model of duchenne muscular dystrophy. Handb Exp Pharmacol 204:323-344.
39. Percival JM, Whitehead NP, Adams ME, Adamo CM, Beavo JA, Froehner SC. 2012. Sildenafil reduces respiratory muscle weakness and fibrosis in the mdx mouse model of Duchenne muscular dystrophy. J Pathol 228:77-87.
40. Rovere-Querini P, Clementi E, Brunelli S. 2014. Nitric oxide and muscle repair: Multiple actions converging on therapeutic efficacy. Eur J Pharmacol 730:181-185.
41. Ruas JL, White JP, Rao RR, Kleiner S, Brannan KT, Harrison BC, Greene NP, Wu J, Estall JL, Irving BA, Lanza IR, Rasbach KA, Okutsu M, Nair KS, Yan Z, Leinwand LA, Spiegelman BM. 2012. A PGC-1α isoform induced by resistance training regulates skeletal muscle hypertrophy. Cell 151:1319-1331.
42. Selsby JT, Morine KJ, Pendrak K, Barton ER, Sweeney HL. 2012. Rescue of dystrophic skeletal muscle by PGC-1α involves a fast to slow fiber type shift in the mdx mouse. PLoS ONE 7:e30063.
43. Serra F, Quarta M, Canato M, Toniolo L, De Arcangelis V, Trotta A, Spath L, Monaco L, Reggiani C, Naro F. 2012. Inflammation in muscular dystrophy and the beneficial effects of non-steroidal anti-inflammatory drugs. Muscle Nerve 46:773-784.
44. Sheffield-Moore M, Wiktorowicz JE, Soman KV, Danesi CP, Kinsky MP, Dillon EL, Randolph KM, Casperson SL, Gore DC, Horstman AM, Lynch JP, Doucet BM, Mettler JA, Ryder JW, Ploutz-Snyder LL, Hsu JW, Jahoor F, Jennings K, White GR, McCammon SD, Durham WJ. 2013. Sildenafil increases muscle protein synthesis and reduces muscle fatigue. Clin Transl Sci 6:463-468.
45. Stamatikos AD, Paton CM. 2013. Role of stearoyl-CoA desaturase-1 in skeletal muscle function and metabolism. Am J Physiol Endocrinol Metab 305:E767-E775.
46. Stamler JS, Meissner G. 2001. Physiology of nitric oxide in skeletal muscle. Physiol Rev 81:209-237.
47. Strimpakos G, Corbi N, Pisani C, Di Certo MG, Onori A, Luvisetto S, Severini C, Gabanella F, Monaco L, Mattei E, Passananti C. 2014. Novel adeno-associated viral vector delivering the utrophin gene regulator jazz counteracts dystrophic pathology in mdx mice. J Cell Physiol 229:1283-1291.
48. Takano K, Watanabe-Takano H, Suetsugu S, Kurita S, Tsujita K, Kimura S, Karatsu T, Takenawa T, Endo T. 2010. Nebulin and N-WASP cooperate to cause IGF-1-induced sarcomeric actin filament formation. Science 330:1536-1540.
49. Tedesco FS, Cossu G. 2012. Stem cell therapies for muscle disorders. Curr Opin Neurol 25:597-603.
50. Witting N, Kruuse C, Nyhuus B, Prahm KP, Citirak G, Lundgaard SJ, von Huth S, Vejlstrup N, Lindberg U, Krag TO, Vissing J. 2014. Effect of Sildenafil on Skeletal and Cardiac muscle in becker muscular dystrophy. Ann Neurol 76:550-557.